Shannon Wakeley, MD
Endocrinology, Diabetes & Metabolism · Lincoln, NENPI 1942350905
Payments from drug & device makers
Across 444 payments — averaging $686.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$224K
- Amgen$36K
- Lilly USA, LLC$7K
- Novo Nordisk$7K
- Ascendis Pharma Endocrinology Inc$6K
- AstraZeneca$5K
- plus $19K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 50 | $224,298 |
| Amgen(2 entities) | 50 | $35,897 |
| Lilly USA, LLC | 63 | $7,232 |
| Novo Nordisk | 50 | $6,826 |
| Ascendis Pharma Endocrinology Inc | 25 | $5,595 |
| AstraZeneca(2 entities) | 24 | $5,425 |
| Boehringer Ingelheim | 12 | $4,612 |
| Sanofi-aventis U.S. LLC | 22 | $4,538 |
| AbbVie | 9 | $3,844 |
| Dexcom, Inc. | 8 | $2,587 |
| Valeritas, Inc. | 9 | $1,796 |
| Ascensia Diabetes Care US Inc. | 23 | $321 |
| Abbott | 15 | $215 |
| Mannkind Corporation | 9 | $202 |
| Corcept Therapeutics | 8 | $184 |
| Tandem Diabetes Care, Inc. | 10 | $150 |
| Antares Pharma, Inc. | 7 | $129 |
| Zealand Pharma US, Inc. | 7 | $116 |
| Amneal Pharmaceuticals LLC | 5 | $84 |
| Insulet Corporation | 3 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Amryt Pharma Holdings Ltd | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $51 |
| BETA Bionics, Inc. | 3 | $49 |
| Ipsen Biopharmaceuticals, Inc | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Nevro Corp. | 2 | $35 |
| Lifescan, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Eisai Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $15 |
| Bayer | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
| IBSA Pharma Inc. | 1 | $11 |
How this compares
$304,705 in reported general payments places this provider in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Lincoln
- Madeline Jones RyanLincoln$281K
- Kara Meinke BaehrLincoln$1K
- Prathima JastiLincoln$1K
- Jalal NafachLincoln$110
- Cyrus DesouzaOmaha$3.6M
- Vijay ShivaswamyOmaha$1.3M
- Robert AndersonOmaha$736K
- Claire BakerOmaha$538K
- Sarah KonigsbergOmaha$251K
- Andjela DrincicOmaha$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.